# Ipamorelin Research: Mechanism, Studies & the GH Axis > Ipamorelin research: the GHS-R1a mechanism, the founding 1998 selectivity study, human pharmacokinetics, the failed Phase 2 trial, and the CJC-1295 combination — cited. The mechanism, the founding study, the human pharmacokinetics, the one trial that tested benefit, and the CJC-1295 combination — each major finding with its citation. ## The short version Ipamorelin research starts with one receptor. The peptide docks onto GHS-R1a — the ghrelin receptor — on pituitary cells and triggers a pulse of growth hormone (GH). The 1998 founding study proved it could do that as strongly as the older peptides while leaving stress hormones alone [1]. From there, the literature splits into three streams: pharmacology (how the body handles it — a clean ~2-hour half-life in humans [2]), efficacy (one human trial, which failed [3], plus animal studies on bone, fat, and weight), and the combination work pairing it with GHRH-type peptides like CJC-1295. The common thread is that the *mechanism* is well established and the *clinical proof of benefit* is not. Below, each finding is stated with its number first and its citation after. ## The mechanism: one receptor, one pulse Ipamorelin activates GHS-R1a (the growth hormone secretagogue receptor type 1a — the ghrelin receptor) on pituitary somatotrophs, the cells that store and release GH. Receptor activation runs through a Gq/PLC signaling pathway that raises intracellular calcium, which triggers GH release [1]. That is a different door into the same cell than GHRH (growth-hormone-releasing hormone) uses, which is exactly why a ghrelin-mimetic and a GHRH-mimetic combine productively. Part of the GH-releasing effect may even start in the gut. Radiolabeled tracing showed that GHRP-class peptides accumulate in the stomach lining — where the body makes its own ghrelin — and removing that tissue cut GHRP-6-driven GH release by 60-70% (but left GHRH-driven release intact) [8]. The reading: these peptides partly work by prompting the body to release its own ghrelin, a peripheral arm of the same axis. Downstream, GH instructs the liver to make IGF-1 (insulin-like growth factor 1), the messenger behind many of GH's slower effects. But that downstream step is context-dependent — it did not show up as a measurable IGF-1 rise in short rodent studies [4]. ## The founding study: selectivity, defined (1998) The paper that put ipamorelin on the map characterized it as "the first selective growth hormone secretagogue" [1]. In rat pituitary cells, anaesthetised rats, and conscious pigs, it released GH about as potently as GHRP-6 (pig ED50 = 2.3 ± 0.03 nmol/kg versus 3.9 nmol/kg for GHRP-6). The headline was what it did *not* do: ACTH and cortisol stayed at the level seen with GHRH alone, even at doses more than 200-fold above the GH-releasing dose [1]. That selectivity is the whole reason ipamorelin is treated differently from its predecessors. GHRP-6 and GHRP-2 raise appetite, cortisol, and prolactin alongside GH; ipamorelin largely confines its action to the GH pulse. Every later use of the peptide — and every research-use protocol built around it — leans on that single result. ## Human pharmacokinetics: clean and dose-proportional (1999) The one rigorous human pharmacology dataset comes from a study in healthy men, eight per dose level, given five 15-minute intravenous infusions spanning 4.21 to 140.45 nmol/kg [2]. The kinetics were textbook: dose-proportional exposure, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg. The GH response came as a single discrete pulse peaking around 40 minutes (0.67 h) after dosing [2]. This tells you how the body clears ipamorelin and how fast GH responds — but it says nothing about whether the peptide produces any lasting benefit. It is a pharmacology result, not an efficacy result, and it remains one of the only human datasets on the compound. ## Does cjc-1295 ipamorelin work On the question "does cjc-1295 ipamorelin work," no trial has tested the combination for any clinical outcome, so the honest answer is that combination efficacy is unproven. What exists is class-level synergy data from a related pairing: a 30-day continuous infusion of GHRP-2 (a ghrelin-receptor agonist in ipamorelin's family) plus GHRH produced significantly greater GH output than either peptide alone in older men and women, and sustained raised IGF-1 without the response fading (p ≤ 0.024) [13]. Acute two-peptide synergy was about 3-fold greater in young than in older volunteers. That study used GHRP-2, not ipamorelin, and tested hormone output — not a health outcome like strength, fat loss, or longevity. So the mechanistic rationale for combining a ghrelin-mimetic with a GHRH-mimetic is sound, but "works" in the sense most people mean it remains unestablished. ## Ipamorelin cjc-1295 The ipamorelin cjc-1295 combination is built on a clean pharmacological logic: ipamorelin hits the ghrelin receptor (GHS-R1a) while CJC-1295 mimics GHRH at the GHRH receptor, so the two push the same GH-releasing cell through two independent doors at once [1]. Co-administering a GHRP with a GHRH analog is the textbook way to amplify a GH pulse, and the GHRP-2 + GHRH synergy data support the principle at the class level [13]. What does not exist is a controlled trial of *this specific pair* for any endpoint. The combination's reputation rests on single-agent pharmacology stitched together, not on combination outcomes. It is a rational design with an empty efficacy column. ## What is cjc 1295 ipamorelin Asking "what is cjc 1295 ipamorelin" is really asking about two separate peptides used together. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist — it triggers a GH pulse without raising cortisol or prolactin [1]. CJC-1295 is a GHRH analog: it mimics growth-hormone-releasing hormone at a different receptor. Paired, they are meant to stimulate GH release through complementary pathways. Neither is FDA-approved, and the combination has never been tested as a unit in a controlled trial. This site documents ipamorelin specifically; CJC-1295 appears here only where the two intersect, and the [how it works](/how-it-works) page draws the GHRP-versus-GHRH distinction out in full. ## Animal efficacy: bone, fat, and the freshest data In rats, subcutaneous ipamorelin at 18, 90, and 450 μg/day (split across three daily doses for 15 days) raised the longitudinal bone growth rate dose-dependently — from 42 μm/day on vehicle to 44, 50, and 52 μm/day — with no measurable change in total IGF-1 or bone-turnover markers [4]. That points to a partly local, pulse-driven skeletal effect rather than a systemic IGF-1 surge. The most recent published in-vivo study is a 2024 ferret experiment: intraperitoneal ipamorelin (1-3 mg/kg) cut cisplatin-driven body-weight loss by about 24% during the delayed phase, but had no effect on chemotherapy nausea (unlike central anamorelin, which reduced acute emesis by 60%) [5]. It is a clean, modern result — a peripheral anti-wasting effect without an anti-nausea one — and the freshest ipamorelin finding on record. One note that keeps the safety picture honest: a 28-day study of a *different* ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats [6]. Ipamorelin was not the tested compound, but it is the kind of class-level signal that explains why chronic dosing of any GH secretagogue warrants caution. --- A plain-English digest of the ipamorelin research — the GH-axis findings explained and cited, with no clinic, no pharmacy, and no prescription behind it.